Profitability Metrics

Gross Margin
25.84%
Operating Margin
5.26%
Net Margin
13.95%

Efficiency Metrics

Revenue per Expense Ratio
1.06
R&D as % of Revenue
2.81%

Earnings Quality

EBITDA Margin
19.69%
Income Tax Rate
11.40%
EPS
8.4400000000

Balance Sheet Analysis

Current Ratio
1.18
Cash Ratio
0.45
Working Capital
$8.92B
Debt to Equity
0.84
Debt to Assets
14.07%
Equity Ratio
16.79%

Cash Flow Analysis

Operating Cash Flow Ratio
7.62%
Free Cash Flow Ratio
5.27%
CapEx to Revenue
2.35%
Dividends Paid
$589.00M
Stock Buybacks
$1.23B
Total Shareholder Returns
$1.82B
Cash Position Change
-3.83%

Key Takeaways (2023 FY)

  • Maintained positive net income growth despite revenue changes
  • Increased R&D investment by 6.77%

Detailed Growth Metrics

Core Performance

Revenue
16.96%
Net Income
2,696.76%
EPS
16,780.00%
Operating Income
1,194.93%

Operational Efficiency

R&D Expenses
6.77%
SG&A Expenses
2.69%
Operating Cash Flow
-12.46%
Free Cash Flow
-24.42%

Balance Sheet Health

Assets
-13.66%
Debt
-12.28%
Book Value per Share
-17.61%
Inventory
10.99%

Shareholder Returns

Dividends per Share
-7.23%
Shares Outstanding
-0.64%

Long Term Trends

3Y Revenue/Share
-9.98%
5Y Revenue/Share
-44.31%
3Y Dividend/Share
-8.69%
5Y Dividend/Share
-86.88%